Morgan Stanley Adaptimmune Therapeutics PLC Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 3,666,061 shares of ADAP stock, worth $109,981. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,666,061

Previous 4,232,268 13.38%

Holding current value

$109,981

Previous $1.02 Million 49.46%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.04 - $0.35 $22,648 - $198,172	-566,207 Reduced 13.38%	3,666,061 $513,000
Q2 2025 Aug 15, 2025	BUY	$0.22 - $0.32 $333,590 - $485,222	1,516,321 Added 55.83%	4,232,268 $1.02 Million
Q1 2025 May 15, 2025	BUY	$0.2 - $0.65 $278,216 - $904,203	1,391,083 Added 105.0%	2,715,947 $543,000
Q4 2024 Feb 14, 2025	SELL	$0.54 - $0.95 $202,046 - $355,452	-374,161 Reduced 22.02%	1,324,864 $715,000
Q3 2024 May 14, 2025	BUY	$0.92 - $1.39 $1.16 Million - $1.75 Million	1,258,193 Added 285.41%	1,699,025 $1.61 Million

Q3 2024 Nov 14, 2024	BUY	$0.92 - $1.39 $1.16 Million - $1.75 Million	1,258,193 Added 285.41%	1,699,025 $1.61 Million
Q2 2024 May 14, 2025	SELL	$0.83 - $1.47 $733,746 - $1.3 Million	-884,032 Reduced 66.73%	440,832 $432,000
Q2 2024 Oct 17, 2024	BUY	$0.83 - $1.47 $56,067 - $99,299	67,551 Added 18.1%	440,832 $432,000
Q2 2024 Aug 14, 2024	BUY	$0.83 - $1.47 $56,067 - $99,299	67,551 Added 18.1%	440,832 $432,000
Q1 2024 Oct 17, 2024	SELL	$0.7 - $1.75 $47,285 - $118,214	-67,551 Reduced 15.32%	373,281 $589,000
Q1 2024 Aug 16, 2024	SELL	$0.7 - $1.75 $1.11 Million - $2.77 Million	-1,583,377 Reduced 80.92%	373,281 $589,000
Q1 2024 May 15, 2024	SELL	$0.7 - $1.75 $1.11 Million - $2.77 Million	-1,583,377 Reduced 80.92%	373,281 $589,000
Q4 2023 Aug 16, 2024	BUY	$0.43 - $0.79 $651,805 - $1.2 Million	1,515,826 Added 343.86%	1,956,658 $1.55 Million
Q4 2023 Feb 13, 2024	SELL	$0.43 - $0.79 $40,715 - $74,803	-94,688 Reduced 4.62%	1,956,658 $1.55 Million
Q3 2023 Nov 15, 2023	SELL	$0.73 - $1.04 $18,852 - $26,859	-25,826 Reduced 1.24%	2,051,346 $1.6 Million
Q2 2023 Aug 14, 2023	SELL	$0.9 - $1.51 $157,726 - $264,630	-175,252 Reduced 7.78%	2,077,172 $1.91 Million
Q1 2023 May 15, 2023	SELL	$1.06 - $2.16 $39,669 - $80,835	-37,424 Reduced 1.63%	2,252,424 $2.46 Million
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $23,186 - $55,867	22,082 Added 0.97%	2,289,848 $3.34 Million
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $198,534 - $451,385	187,297 Added 9.0%	2,267,766 $2.44 Million
Q2 2022 Oct 27, 2022	BUY	$1.33 - $2.28 $35,955 - $61,637	27,034 Added 1.32%	2,080,469 $3.54 Million
Q2 2022 Aug 15, 2022	BUY	$1.33 - $2.28 $35,955 - $61,637	27,034 Added 1.32%	2,080,469 $3.54 Million
Q1 2022 Oct 27, 2022	SELL	$1.73 - $4.06 $46,768 - $109,758	-27,034 Reduced 1.3%	2,053,435 $4.23 Million
Q1 2022 May 13, 2022	SELL	$1.73 - $4.06 $328,765 - $771,554	-190,038 Reduced 8.47%	2,053,435 $4.23 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $6.68 Million - $10.8 Million	1,908,502 Added 569.75%	2,243,473 $8.41 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $1.15 Million - $2.13 Million	334,971 New	334,971 $1.73 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

42M

Call Options Held

139K

Put Options Held

144K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $4.9M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account